151 related articles for article (PubMed ID: 18588997)
1. Drug development and IBS drugs: experience from the past, current challenges, and proposal for the future.
Camilleri M
Curr Opin Pharmacol; 2008 Dec; 8(6):671-6. PubMed ID: 18588997
[TBL] [Abstract][Full Text] [Related]
2. Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles.
Camilleri M; Chang L
Gastroenterology; 2008 Dec; 135(6):1877-91. PubMed ID: 18848833
[TBL] [Abstract][Full Text] [Related]
3. Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome.
Mangel AW; Bornstein JD; Hamm LR; Buda J; Wang J; Irish W; Urso D
Aliment Pharmacol Ther; 2008 Jul; 28(2):239-49. PubMed ID: 18466359
[TBL] [Abstract][Full Text] [Related]
4. Design of treatment trials in irritable bowel syndrome: opioid agonists and atypical benzodiazepine antagonists.
Mangel AW; Fehnel SE
Neurogastroenterol Motil; 2008 Oct; 20(10):1086-93. PubMed ID: 18826559
[TBL] [Abstract][Full Text] [Related]
5. FDA and EMA end points: which outcome end points should we use in clinical trials in patients with irritable bowel syndrome?
Corsetti M; Tack J
Neurogastroenterol Motil; 2013 Jun; 25(6):453-7. PubMed ID: 23672677
[TBL] [Abstract][Full Text] [Related]
6. Personal view: adequate relief as a primary endpoint in irritable bowel syndrome.
Mangel AW
Aliment Pharmacol Ther; 2006 Apr; 23(7):879-81. PubMed ID: 16573790
[TBL] [Abstract][Full Text] [Related]
7. Investigational agents for the irritable bowel syndrome.
Ghaith O; El-Halabi M; Hashash JG; Sharara AI
Expert Opin Investig Drugs; 2010 Oct; 19(10):1161-78. PubMed ID: 20836617
[TBL] [Abstract][Full Text] [Related]
8. [Tegaserod in treatment of women with irritable bowel syndrome].
Munck LK; Ainsworth MA
Ugeskr Laeger; 2007 Jun; 169(23):2190-2. PubMed ID: 17592683
[TBL] [Abstract][Full Text] [Related]
9. End points in irritable bowel syndrome.
Mangel AW; Fehnel SE
Expert Rev Gastroenterol Hepatol; 2011 Jun; 5(3):293-5. PubMed ID: 21651345
[No Abstract] [Full Text] [Related]
10. Pathophysiological concepts of functional dyspepsia and irritable bowel syndrome future pharmacotherapy.
Dobrek Ł; Thor PJ
Acta Pol Pharm; 2009; 66(5):447-60. PubMed ID: 19894640
[TBL] [Abstract][Full Text] [Related]
11. Randomized, double-blind, placebo-controlled trial of the 5-HT1A receptor antagonist AZD7371 tartrate monohydrate (robalzotan tartrate monohydrate) in patients with irritable bowel syndrome.
Drossman DA; Danilewitz M; Naesdal J; Hwang C; Adler J; Silberg DG
Am J Gastroenterol; 2008 Oct; 103(10):2562-9. PubMed ID: 18775020
[TBL] [Abstract][Full Text] [Related]
12. Serotonergic agents and the irritable bowel syndrome: what goes wrong?
Spiller R
Curr Opin Pharmacol; 2008 Dec; 8(6):709-14. PubMed ID: 18672092
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological treatment of functional bowel disorders: any light at the end of the tunnel?
Boeckxstaens GE
Curr Opin Pharmacol; 2008 Dec; 8(6):669-70. PubMed ID: 18835367
[No Abstract] [Full Text] [Related]
14. Irritable bowel syndrome: a mild disorder; purely symptomatic treatment.
Prescrire Int; 2009 Apr; 18(100):75-9. PubMed ID: 19585728
[TBL] [Abstract][Full Text] [Related]
15. The FDA and IBS drug development.
Mangel AW
Am J Gastroenterol; 2009 Dec; 104(12):3106; author reply 3106. PubMed ID: 19956135
[No Abstract] [Full Text] [Related]
16. Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints.
Camilleri M; Mangel AW; Fehnel SE; Drossman DA; Mayer EA; Talley NJ
Clin Gastroenterol Hepatol; 2007 May; 5(5):534-40. PubMed ID: 17428741
[TBL] [Abstract][Full Text] [Related]
17. The FDA's decision-making process: isn't it time to temper the principle of protective paternalism?
Brandt LJ
Am J Gastroenterol; 2008 May; 103(5):1226-7. PubMed ID: 18477347
[TBL] [Abstract][Full Text] [Related]
18. Duloxetine in the treatment of irritable bowel syndrome: an open-label pilot study.
Brennan BP; Fogarty KV; Roberts JL; Reynolds KA; Pope HG; Hudson JI
Hum Psychopharmacol; 2009 Jul; 24(5):423-8. PubMed ID: 19548294
[TBL] [Abstract][Full Text] [Related]
19. Drug evaluation: Pumosetrag for the treatment of irritable bowel syndrome and gastroesophageal reflux disease.
Evangelista S
Curr Opin Investig Drugs; 2007 May; 8(5):416-22. PubMed ID: 17520871
[TBL] [Abstract][Full Text] [Related]
20. Tegaserod in patients with irritable bowel syndrome.
Schooff M; Stelter C
Am Fam Physician; 2004 Dec; 70(11):2107-8. PubMed ID: 15606056
[No Abstract] [Full Text] [Related]
[Next] [New Search]
